Non-surgical repositioning of dexamethasone implant (Ozurdex®) fragment in a case of anterior chamber migration

Reposicionamento não cirúrgico de fragmento de implante de dexametasona (ozurdex®) em caso de migração para câmara anterior

ABSTRACT

The authors report a case of non-surgical repositioning of a fragment of a dexamethasone implant that migrated to the anterior chamber. A 66-year-old male with aphakia and a history of cataract surgery evolving with dislocation of the lens to the vitreous cavity. Optical coherence tomography (OCT) revealed cystoid macular edema, with the therapeutic indication of an intravitreal dexamethasone implant. On biomicroscopy, he presented a fragment of the implant in the inferior anterior chamber. The standard treatment is surgical repositioning. However, an extrinsic ocular mobilization technique was used, which successfully non-surgical replacement of the implant to the vitreous cavity.

Keywords: Dexamethasone; Anterior Chamber; Ophthalmologic Surgical Procedures; Eye manifestations.

RESUMEN

Los autores relatan un caso sobre el reposicionamiento no quirúrgico de un fragmento de implante de dexametasona, el cual migró para la cámara anterior. Paciente de 66 años, masculino, afálico, con histórico de cirugía de catarata, evolucionando con luxación de lente para cavidad vitrea. En el examen de OCT, se constató edema macular cistoide, con indicación terapéutica de implante intraocular de dexametasona. A biomicroscopia, presentaba un fragmento del corticoide posicionado en la cámara anterior, inferiormente. El tratamiento estándar es el reposicionamiento quirúrgico, entretanto, utilizamos una técnica de movimentación ocular extrínseca, a la cual recolocó con éxito el fragmento para la cavidad vitrea.

Palabras clave: Dexametasona; Cámara Anterior; Procedimientos Cirúrgicos Oftalmológicos; Manifestaciones Oculares.

Funding: No specific financial support was available for this study.
CEP Approval: Not applicable.
Disclosure of potential conflicts of interest: None of the authors have any potential conflict of interest to disclose.
Received on: Mar 20, 2018
Accepted on: Apr 06, 2018
Corresponding author: Paulo Sérgio Miranda de Oliveira Filho – Universidade Federal do Pará, Rua Augusto Corrêa, 1, Belém, PA, 66075-110. psmoliveiramd@gmail.com

How to cite: Rosa AAM; Mendes TS; Oliveira Filho PSM. Reposicionamento não cirúrgico de fragmento de implante de dexametasona (ozur-dex) em caso de migração para câmara anterior. eOftalmo. 2018: 4(2): 74-79.
http://dx.doi.org/10.17545/eoftalmo/2018.0013

eOftalmo. 2018; 4(2): 74-79. CreativeCommons Atribuição-NãoComercial 4.0 Internacional
INTRODUCTION

Dexamethasone ocular implants (Ozurdex®, Allergan, Inc., Irvine, CA) are rod-shaped, made of a biodegradable polymer, and 6-mm long and 0.46-mm wide and contain 0.7 mg of the drug, which is gradually released into the posterior chamber of the patient’s ocular globe over months.1,2 It is indicated in cases of macular edema associated with retinal vein occlusions, non-infectious posterior uveites, and diabetic macular edema.1,2,3

Cataract formation, increased intraocular pressure (IOP), and secondary glaucoma are possible complications from the use of this medication.1 IOP is defined by the balance between the production and drainage of aqueous humor, and it varies according to anatomical and physiological factors. The value considered normal for tonometry varies from 11 to 21 mmHg. These numbers can fluctuate during the day, influenced by various factors, such as arterial pressure and even breathing.4

The main pathology associated with high IOP as a risk factor is glaucoma, whose symptoms are associated with the progressive loss of the visual field due to damage to retinal ganglion cells. However, patients with IOP parameters fluctuating within the normal range can also develop glaucoma because it is a multifactorial disease. Processes such as alterations in retinal microcirculation, changes in immunity and oxidative stress are possible factors that trigger glaucoma.4,5

Glaucoma affects approximately 3% of the population aged more than 40 years, a number estimated at 70 million patients worldwide. In Brazil, it is estimated that there are approximately 985,000 patients with glaucoma aged more than 40 years, 70% of whom have not yet been diagnosed.4,5,6

Some reports show the possibility of segmentation/breakage of the implant inside the ocular cavity at the time of application, which mainly occurs due to manufacturing defects.4 There is also a chance of migration of the implant to the anterior chamber in patients with aphakia, which can lead to the development of corneal edema with associated endothelial injury and, consequently, increased IOP.7,8,9

The management of implant dislocation is essentially surgical to avoid complications from the presence of the medication in the anterior segment. However, in this report we describe the relocation of an implant fragment that had migrated to the anterior chamber, using a simple, non-surgical technique of ocular mobilization.

CASE REPORT

A 66-year-old male (initials V.P.S.) from Belém, State of Pará, Brazil, referred for ophthalmological evaluation with a complaint of poor visual acuity in the right eye for the past 5 months.

Personal history had no clinical relevance. Ocular history was as follows: the patient had a history of cataract surgery in the right eye with complications (August 2014), evolving with dislocation of the intraocular lens to the vitreous cavity, which later required a posterior vitrectomy. Subsequently, an anterior-chamber intraocular lens was surgically implanted (September 2014).

Biomicroscopy examination revealed an intact cornea, a regular pupil, and a well-positioned anterior-chamber intraocular lens (Figure 1). On retinal examination, we observed a 0.5 papillary excavation with foveal thickening of petaloid aspect.

In the initial (OCT) assessment, we observed cystoid macular edema (Figure 2).

A dexamethasone implant in the right eye was indicated and performed without complications. In the postoperative room, the patient complained of seeing a foreign body in front of the eye. In the biomicroscopy examination, we observed an intact cornea, with a polymer fragment in the inferior portion of the anterior chamber (Figure 1). The patient was positioned in dorsal horizontal decubitus and a maneuver was performed to reposi- tion the polymer (Video 1), which was successful, as we can see in the retinography (Figure 3) with the polymer fragment once again inside the vitreous cavity located inferiorly.

The goal of the ocular mobilization maneuver was to spare the patient from an invasive approach. In an outpatient consultation room, the patient was positioned in dorsal decubitus under good lighting. Initially, the right eye was mobilized superiorly, with a posterior movement in the nasal direction followed by superior-medial positioning. The eye was repositioned superiorly, followed by a lateral movement, and subsequently returned to the superior position. The patient was instructed to move the eye inferiorly and position it superiorly on two subsequent occasions. At this point, the fragment had been successfully repositioned to the posterior chamber. After 7 days, the implant fragment remained in the vitreous cavity.
DISCUSSION

Most common indications for using the Ozurdex® implant are macular edema associated with retinal vein occlusions or non-infectious posterior uveites and diabetic macular edema.\textsuperscript{1,2,3} Its use is also described in patients with cystoid macular edema following cataract surgery, also called the Irvine–Gass syndrome.\textsuperscript{10}

Corticosteroids play a key role in the treatment of retinal disease, particularly in cystoid macular edema, which results from the breakdown of the bloodretinal barrier, accompanied by an increase in inflammatory mediators. In patients with diabetes, the focus is on the suppression of leukocyte adhesion, which leads to a decrease in protein levels, less overload on the hematoretinal barrier, and therefore less endothelial growth factor (VEGF) activity.\textsuperscript{11}
As we saw in the patient described in the present report, the implant was indicated because of cystoid macular edema that was confirmed in the consultation, with a possible postsurgical etiology of complications from cataract surgery and anterior chamber lens implant, which can be responsible for causing subclinical uveitis and an increase of inflammatory products, which in turn are responsible for injuring the corneal endothelium.12

The implant is performed by a microsurgery technique, using an applicator pre-loaded with the biodegradable rod-shaped medication. The possibility of implant breakage is associated with manufacturing problems, although there is the possibility of breakage with the normal process of wear. According to the manufacturer, in cases of breakage, there are no changes in the pharmacokinetics, time of action, or expected effects of the medication.8

Another complication is the dislocation of the dexamethasone implant to the anterior chamber of the eye, which is uncommon, even in the presence of an intraocular lens, with a higher incidence in patients with aphakia and pseudoaphakia. Patients with a history of vitrectomy are also at higher risk.9

To prevent this dislocation during follow-up, the patient should avoid physical exertion, prone or face-down positions, and flights for long duration, because the difference in pressure between the body and the airplane may dislocate the implant to the anterior chamber.7

This dislocation is associated with the development of corneal edema, which is the main complication. The mechanism observed is due to the toxicity of the degradation of the drug into lactic acid or glycolic acid. Trauma from the presence of a foreign body cannot be ruled out.9 Specular microscopy shows the loss of corneal endothelial cells in cases of implant migration. However, it is known that the use of low doses of dexamethasone is well tolerated in the treatment of inflammation following cataract surgery.13

It is also known that approximately 12% of the patients in the GENEVA study developed ocular hypertension following a single implant treatment. However, the Shasta study shows that only 1.7% of the patients with increased IOP due to the use of the medication will undergo surgery for glaucoma, which indicates that the effect of the corticosteroid in increasing the IOP is transitory.14

The implant is repositioned surgically in some cases, but it is possible to use a 30G needle and a slit lamp under local anesthesia to reposition the implant to the posterior chamber. These techniques reduce the need for surgical intervention, reducing the risk inherent in the procedure.7,15,16

In the present case, there were two unusual occurrences: the breakage of the implant into two pieces and the dislocation of one of the fragments into the anterior chamber. The patient had the risk factors for this mobilization, i.e., anterior chamber lens for aphakia and prior vitrectomy, although the presence of these factors does not necessarily mean that dislocation will occur. We observed corneal edema with Descemet’s folds from the patient’s delay in returning to the clinic. In this case, the non-surgical implant repositioning option was chosen, as...
it would reduce patient risk, associated with the fact that dislocation of only one of the fragments had occurred, which we believe to have facilitated the success of the non-surgical repositioning.

CONCLUSION

Dexamethasone implants present low patient risks when compared to the benefits of treatment. However, the possibility of dislocation of the medication to the anterior chamber, particularly in cases of patients with aphakia with implant fragmentation and prior vitrectomy, cannot be ignored. The indicated treatment is surgical removal, but in cases like the one presented, it is possible to relocate the implant fragment using an ocular movement technique, thereby preventing corneal edema and increased IOP.

REFERENCES

Repositioning of dexamethasone implant fragment

Alexandre Antônio Marques Rosa
https://orcid.org/0000-0001-5496-9704
http://lattes.cnpq.br/4972772795172243

Thais Sousa Mendes
http://orcid.org/0000-0001-5568-9958
http://lattes.cnpq.br/017536091663758

Paulo Sérgio Miranda de Oliveira Filho
https://orcid.org/0000-0002-7382-9544
http://lattes.cnpq.br/4420082065395077